OTC:IPCIF   Intellipharmaceutics International Inc.
28th fda catalyst
評論:
Fundamentals are very poor, last submission to FDA failed making the stakes very high for long term investors, could start to push bearish under the support level.
評論:
Either that or big corps will interfere putting funds in for a bullish look grabbing the attention of traders to push upwards.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。